To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Digoxin is associated wit… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction

Journal article
Authors J. M. Zhou
J. Cao
X. J. Jin
J. Zhou
Z. Y. Chen
D. L. Xu
X. C. Yang
W. Dong
L. W. Li
Y. Y. Fan
L. Chen
Q. Q. Zhong
Michael Fu
K. Hu
J. B. Ge
Y. M. Lu
G. H. Zhang
Chen Li
H. M. Gu
M. Wei
L. L. Chen
J. Wang
Z. Y. Yang
H. G. Jin
X. L. Li
Z. Y. Qiao
Y. J. Yang
Y. L. Zhao
R. Jia
B. Hong
F. Yuan
J. F. Wang
J. Ma
Y. Xu
M. Wahafu
Q. Yu
C. Q. Wang
C. W. Ruan
H. G. Fu
X. B. Liu
X. Xu
S. P. Chen
Q. L. Liu
B. Shi
J. H. Xu
Published in Esc Heart Failure
Volume 7
Issue 1
Pages 139-147
ISSN 2055-5822
Publication year 2020
Published at Institute of Medicine
Pages 139-147
Language en
Keywords Digoxin, Heart failure, Atrial fibrillation, Prognosis, clinical characteristics, mortality, risk, guidelines, withdrawal, trial, Cardiovascular System & Cardiology
Subject categories Cardiac and Cardiovascular Systems


Aims The aim of this study was to investigate the impact of digoxin use on the outcomes of patients with heart failure with reduced ejection fraction (HFrEF) and its possible interaction with atrial fibrillation or use of currently guideline-recommended treatments in the real world in China. Methods and results Patients hospitalized with HFrEF from 45 hospitals participating in the China National Heart Failure Registration Study (CN-HF) were enrolled to assess the all-cause mortality, HF mortality, all-cause re-hospitalization, and HF re-hospitalization associated with digoxin use. Eight hundred eighty-two eligible HFrEF patients in the CN-HF registry were included: 372 patients with digoxin and 510 patients without digoxin. Among them, 794 (90.0%) patients were followed up for the endpoint events, with a median follow-up of 28.6 months. Kaplan-Meier survival analysis showed that the all-cause mortality (P < 0.001) and all-cause re-hospitalization (P = 0.020) were significantly higher in digoxin group than non-digoxin group, while HF mortality (P = 0.232) and HF re-hospitalization (P = 0.098) were similar between the two groups. The adjusted Cox proportional-hazards regression analysis demonstrated that digoxin use remained as an independent risk factor for increased all-cause mortality [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.27-2.44; P = 0.001] and all-cause re-hospitalization (HR 1.27; 95% CI 1.03-1.57; P = 0.029) in HFrEF patients and the predictive value of digoxin for all-cause mortality irrespective of rhythm or in combination with other guideline-recommended therapies. Conclusions Digoxin use is independently associated with increased risk of all-cause mortality and all-cause re-hospitalization in HFrEF patients.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?